CompletedPhase 3NCT01709942

Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS)

Studying Ovarian hyperstimulation syndrome

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Centre for Endocrinology and Reproductive Medicine, Italy
Principal Investigator: Marco Sbracia, MD
Centre for Endocrinology and Reproductive Medicine, Italy
Intervention: degarelix (long acting GnRH antagonist)(drug)
Enrollment: 80 target
Eligibility: 20-38 years · FEMALE
Timeline: 2012 – 2015

Study locations (1)

Cerm-Hungaria, Rome, Italy

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01709942 on ClinicalTrials.gov

Other trials for Ovarian hyperstimulation syndrome

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE2NCT07043322
Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome
Tanta University

See all trials for Ovarian hyperstimulation syndrome →

← Back to all trials